Search results
Results from the WOW.Com Content Network
CRISPR interference (CRISPRi) is a genetic perturbation technique that allows for sequence-specific repression of gene expression in prokaryotic and eukaryotic cells. [1] It was first developed by Stanley Qi and colleagues in the laboratories of Wendell Lim , Adam Arkin, Jonathan Weissman , and Jennifer Doudna . [ 2 ]
On 26 November 2018, The CRISPR Journal published ahead of print an article by He, Ryan Ferrell, Chen Yuanlin, Qin Jinzhou, and Chen Yangran in which the authors justified the ethical use of CRISPR gene editing in humans. [74] As the news of CRISPR babies broke out, the editors reexamined the paper and retracted it on 28 December, announcing:
CRISPR-Cas9 genome editing techniques have many potential applications. The use of the CRISPR-Cas9-gRNA complex for genome editing [10] was the AAAS's choice for Breakthrough of the Year in 2015. [11] Many bioethical concerns have been raised about the prospect of using CRISPR for germline editing, especially in human embryos. [12]
Diagram showing type I-F CRISPR-Cas system, as well as inhibition mechanisms of three type I-F anti-CRISPRs. Type I-F CRISPR complex is made of 60 crRNA nucleotides and nine Cas proteins (the protein type is specified by the numbers 5,8,7,6). AcrF1 goes to Cas7f, preventing target DNA access to the crRNA guide.
Off-target genome editing refers to nonspecific and unintended genetic modifications that can arise through the use of engineered nuclease technologies such as: clustered, regularly interspaced, short palindromic repeats ()-Cas9, transcription activator-like effector nucleases (), meganucleases, and zinc finger nucleases (ZFN). [1]
A 2013 review, of 1,783 papers on genetically modified crops and food published between 2002 and 2012 found no plausible evidence of dangers from the use of then marketed GM crops. [ 13 ] In a 2014 review, Zdziarski et al. examined 21 published studies of the histopathology of GI tracts of rats that were fed diets derived from GM crops, and ...
For teens who were born in 2007, 52.8% of those who were not eligible for VFC were up to date on their HPV vaccines by age 13. By comparison, only 48.7% of non-eligible teens born in 2010 were up ...
[75]: 5 As of 2017, such vectors were used in 20% of trials for gene therapy. [74]: 10 Adenovirus vectors are mostly used in cancer treatments and novel genetic vaccines such as the Ebola vaccine, vaccines used in clinical trials for HIV and SARS-CoV-2, or cancer vaccines. [75]: 5